Loading patent…
AssigneeDBV Technologies
InventorsVincent DIOSZEGHY, Katie MATTHEWS, Pierre-Louis HERVE, Camille ROUCAIROL, Stef KOPPELMAN, Robert Paul ANDERSON, Frits KONING, Bernard Maillere
Estimating the term…
The present application relates to a method for increasing tolerance to gliadin in a subject, in particular in a subject suffering from celiac disease, comprising repeatedly administered a polypeptide construct comprising several epitopes from gliadin isoforms preferably by epicutaneous route. The present application also relates to the polypeptide construct per se and a skin patch containing the same.
-45. (canceled)
An immunogenic polypeptide construct which comprises the four building blocks BB1, BB2, BB3, and BB4, wherein BB1 is a polypeptide of SEQ ID NO:83, BB2 is a polypeptide of SEQ ID NO:84, BB3 is a polypeptide of SEQ ID NO:85, and BB4 is a polypeptide of SEQ ID NO:86 and wherein BB1, BB2, BB3, and BB4 are directly connected or connected by means of one or more polypeptide linkers in order BB1, BB2, BB3, BB4.
Dependencies are inferred from the claim text.